Lack of Association among Peptidyl Arginine Deiminase Type 4 Autoantibodies, PADI4 Polymorphisms, and Clinical Characteristics in Rheumatoid Arthritis.

CONCLUSION: Taken together, the results from these combined serological, genetic, and clinical analyses suggest that anti-PAD4 appears to be a bystander autoantibody with no current clinical utility in RA. PMID: 29858238 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29858238?dopt=Abstract

Source: J Rheumatol - June 1, 2018 Category: Rheumatology Authors: Guderud K, Mæhlen MT, Nordang GBN, Viken MK, Andreassen BK, Molberg Ø, Flåm ST, Lie BA Tags: J Rheumatol Source Type: research

More News: Arthritis | Genetics | Rheumatoid Arthritis | Rheumatology | Study